Strategic Alliance Partnership | Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

Check out the top 5 nutrition articles of 2025. A large observational cohort study conducted at Kaiser Permanente Northern California during the 2023–2024 RSV season found that nirsevimab was highly ...

Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

The FDA approved Daybue Stix, a powder formulation of trofinetide, for Rett syndrome in patients 2 years or older. New formulation, same clinical expectations: The FDA approval of DAYBUE STIX provides ...

Berotralstat becomes the first targeted oral prophylactic therapy for patients with HAE 2 years or older. The rare, inherited disease is characterized by unpredictable, potentially life-threatening ...

“Having a drug that [patients] can be confident in that will be highly effective as well as well tolerated is a great advantage," said Edward Hook, MD. The FDA recently approved Nuzolvence ...

According to multiple reports, the FDA is investigating the safety of a pair of already-approved protective treatments for respiratory syncytial virus. The FDA is launching a new safety review of the ...

Phase 3 results show oral zoliflodacin was noninferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea. Phase 3 trial showed non-inferiority of a single oral dose of ...

Following an updated policy from the American Academy of Child and Adolescent Psychiatry, Joshua Feder, MD, explains why providers should present DRBIs and NDBIs as options for autism care.